DailyDoctor Archive Specialties Get app
All infectious diseases briefings

The edition · Infectious Diseases

Adding chlorhexidine to ICU oral care did not prevent ventilator pneumonia in an Indian trial

A cluster-randomised crossover trial in six medical ICUs in Bhubaneswar found no benefit and slightly longer stays. Also: daptomycin dosing for enterococci, a community stewardship trial, and a linezolid label action.

The edition in brief

A pragmatic cluster-randomised crossover trial in six medical ICUs at one Indian hospital (1,035 ventilated adults) found that adding 0.12% chlorhexidine to a standardised oral-care bundle did not lower ventilator-associated pneumonia (IRR 1.08, CI 0.84–1.38) or 28-day mortality, and ICU stay was about 0.9 days longer. A Lancet Infectious Diseases review argues daptomycin for enterococcal bacteraemia and endocarditis is often underdosed, proposing at least 8 mg/kg daily for E faecium, 10–12 mg/kg for vancomycin-resistant disease, beta-lactam combination in endocarditis and weekly CK monitoring. A cluster-randomised trial in Burkina Faso and DR Congo found a community and provider education bundle based on WHO AWaRe cut Watch-group antibiotic use (adjusted prevalence ratio 0.33). The FDA recorded a supplemental action on the linezolid (Zyvox) application; the record does not specify the change. The pearl covers linezolid monitoring.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free